Compare LAB & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAB | KMDA |
|---|---|---|
| Founded | 1999 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.1M | 488.6M |
| IPO Year | 2008 | 2013 |
| Metric | LAB | KMDA |
|---|---|---|
| Price | $0.98 | $8.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.35 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 2.4M | 56.4K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 2.97% |
| EPS Growth | ★ 61.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $101,937,000.00 | N/A |
| Revenue This Year | N/A | $13.94 |
| Revenue Next Year | $2.63 | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | $6.35 |
| 52 Week High | $1.72 | $9.35 |
| Indicator | LAB | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 47.88 |
| Support Level | $0.92 | $8.38 |
| Resistance Level | $1.01 | $8.88 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 88.90 | 68.25 |
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.